Literature DB >> 10465111

Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi.

T Papp1, H Pemsel, R Zimmermann, R Bastrop, D G Weiss, D Schiffmann.   

Abstract

Eighteen human congenital melanocytic naevi (CMN) from 17 patients were screened for activating point mutations in the oncogenes N-ras and CDK4 and for sequence variants in the MC1R gene by combined RFLP-PCR/SSCP analysis. In addition, all lesions were screened for deletions and point mutations in the tumour suppressor genes p53 and p16INK4a (CDKN2A) by combined multiplex PCR/SSCP analysis. Positive screening data were specified by sequencing of the corresponding PCR product. Activating point mutations in the N-ras gene (nine CAA (Gln) to AAA (Lys) transversions and one CAA (Gln) to CGA (Arg) transition at codon 61) were detected at high frequency (56%). Furthermore, three missense mutations (V92M) and two silent mutations (CGA (Arg) to CGG (Arg), codon 213, exon 6) were found in the MC1R and p53 genes, respectively. No mutations were found in p16 or CDK4. The activated N-ras oncogene, which is also found in human cutaneous melanomas, may constitute a potential risk factor for melanoma formation within CMN.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10465111      PMCID: PMC1762982     

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  44 in total

Review 1.  Congenital nevi.

Authors:  S M Schleicher; S J Lim
Journal:  Int J Dermatol       Date:  1995-12       Impact factor: 2.736

Review 2.  DNA damage profiles induced by oxidizing agents.

Authors:  B Epe
Journal:  Rev Physiol Biochem Pharmacol       Date:  1996       Impact factor: 5.545

Review 3.  Molecular genetics of exocrine pancreatic neoplasms.

Authors:  S A Hahn; S E Kern
Journal:  Surg Clin North Am       Date:  1995-10       Impact factor: 2.741

4.  Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma.

Authors:  A van Elsas; S F Zerp; S van der Flier; K M Krüse; C Aarnoudse; N K Hayward; D J Ruiter; P I Schrier
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

Review 5.  Biological and clinical importance of the p53 tumor suppressor gene.

Authors:  V E Velculescu; W S El-Deiry
Journal:  Clin Chem       Date:  1996-06       Impact factor: 8.327

6.  Frequency of homozygous deletion at p16/CDKN2 in primary human tumours.

Authors:  P Cairns; T J Polascik; Y Eby; K Tokino; J Califano; A Merlo; L Mao; J Herath; R Jenkins; W Westra; J L Rutter; A Buckler; E Gabrielson; M Tockman; K R Cho; L Hedrick; G S Bova; W Isaacs; W Koch; D Schwab; D Sidransky
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

7.  Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans.

Authors:  P Valverde; E Healy; I Jackson; J L Rees; A J Thody
Journal:  Nat Genet       Date:  1995-11       Impact factor: 38.330

8.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.

Authors:  T Wölfel; M Hauer; J Schneider; M Serrano; C Wölfel; E Klehmann-Hieb; E De Plaen; T Hankeln; K H Meyer zum Büschenfelde; D Beach
Journal:  Science       Date:  1995-09-01       Impact factor: 47.728

9.  Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.

Authors:  J A Reed; F Loganzo; C R Shea; G J Walker; J F Flores; J M Glendening; J K Bogdany; M J Shiel; F G Haluska; J W Fountain
Journal:  Cancer Res       Date:  1995-07-01       Impact factor: 12.701

10.  Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression.

Authors:  N A Gruis; J Weaver-Feldhaus; Q Liu; C Frye; R Eeles; I Orlow; L Lacombe; V Ponce-Castaneda; P Lianes; E Latres
Journal:  Am J Pathol       Date:  1995-05       Impact factor: 4.307

View more
  29 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

Review 2.  Assessing cell and organ senescence biomarkers.

Authors:  Bruno Bernardes de Jesus; Maria A Blasco
Journal:  Circ Res       Date:  2012-06-22       Impact factor: 17.367

Review 3.  Growth factors and oncogenes as targets in melanoma: lost in translation?

Authors:  Lawrence Kwong; Lynda Chin; Stephan N Wagner
Journal:  Adv Dermatol       Date:  2007

4.  NRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic nevi.

Authors:  Christelle Charbel; Romain H Fontaine; Gabriel G Malouf; Arnaud Picard; Natacha Kadlub; Nizar El-Murr; Alexandre How-Kit; Xiaoping Su; Aurore Coulomb-L'Hermine; Jorg Tost; Samia Mourah; Selim Aractingi; Sarah Guégan
Journal:  J Invest Dermatol       Date:  2013-10-15       Impact factor: 8.551

Review 5.  [Molecular diagnostics in melanoma].

Authors:  R Lang; J W Bauer; M Laimer
Journal:  Hautarzt       Date:  2015-04       Impact factor: 0.751

6.  Oncogenic NRAS cooperates with p53 loss to generate melanoma in zebrafish.

Authors:  Michael Dovey; Richard Mark White; Leonard I Zon
Journal:  Zebrafish       Date:  2009-12       Impact factor: 1.985

Review 7.  Chemoprevention of melanoma.

Authors:  Marie-France Demierre; Glenn Merlino
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

Review 8.  Genetic and environmental melanoma models in fish.

Authors:  E Elizabeth Patton; David L Mitchell; Rodney S Nairn
Journal:  Pigment Cell Melanoma Res       Date:  2010-03-08       Impact factor: 4.693

9.  Genetics of uveal melanoma and cutaneous melanoma: two of a kind?

Authors:  Thomas van den Bosch; Emine Kilic; Dion Paridaens; Annelies de Klein
Journal:  Dermatol Res Pract       Date:  2010-06-06

10.  The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence.

Authors:  Sebastian Haferkamp; Sieu L Tran; Therese M Becker; Lyndee L Scurr; Richard F Kefford; Helen Rizos
Journal:  Aging (Albany NY)       Date:  2009-05-16       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.